Olaparib in the therapy of advanced ovarian cancer: first real world experiences in safety and efficacy from China

• Autori principali: Jing Ni (Autore), Xianzhong Cheng (Autore), Rui Zhou (Autore), Xia Xu (Autore), Wenwen Guo (Autore), Xiaoxiang Chen (Autore)
• Natura: Libro
• Pubblicazione: BMC, 2019-11-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Abstract Purpose Poly (ADP-ribose) polymerase (PARP) inhibitor, is a milestone in treatment of ovarian cancer. However, there is no real world study from China regarding the clinical outcome of the taking PARP inhibitor (PARPi), Olaparib(Lynparza™). The goal of this research is to evaluate the side...